Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>Resources>Posters

  Posters

Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong

Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.

A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
Mira Genser-Nir, Sharon Daniliuc, Marina Tevrovsky, Roni Hazan Brill, Yuliya-Yael Miropolski, David Fiorentini.

An overview of a novel SF, XF differentiation system which enables achieving defined conditions for rapid generation of differentiated hMSCs towards tissue engineering and drug screening applications

A Synthetic CRISPR-Cas9 System for Homology-directed Repair
John A. Schiel, Maren M. Gross, Emily M. Anderson*, Eldon T. Chou, Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA

Synthetic, dual-RNA-encoded Cas9 is used for precise homology-directed repair (HDR) gene engineering. Both short and long (GFP) inserts are covered.

Phenotypic Cell-Based Screening of a High Content Imaging Cell Health Assay using the IN Cell Analyzer 2000
Zaynab Neetoo-Isseljee, Chido Mpamhanga, David Tickle, Debra Taylor and Janet Brownlees

A High Content Imaging Cell Health assay has been established in-house for phenotypic High Content Screening using the IN Cell Analyzer 2000 and Genedata Screener analysis software. We describe the assay development and initial screening of the FDA set in HepG2 cells for validation of the assay.

CRISPR-Cas9 genome editing utilizing chemically synthesized RNA
Kaizhang He, Eldon Chou, Amanda Haas, ┼Żaklina Strezoska, Melissa L. Kelley, and Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA

CRISPR-Cas9 gene editing using synthetic crRNA:tracrRNA or sgRNA is highly efficient and easy to use. Synthetic crRNA:tracrRNA is uniquely suited to in vitro and in vivo applications, in particular, DNA-free approach with Cas9 mRNA. Chemical synthesis of guide RNAs allows accurate and rapid production of arrayed crRNA libraries for high-confidence, loss-of-function screens.

The Case for CASE: Computer-Assisted Structure Elucidation
ACD/Labs

Modern CASE systems such as Structure Elucidator Suite provide the necessary capability accurately elucidate a novel chemical structure for complex molecules based on readily available NMR data sets. This allows organizations to avoid expensive, labor-intensive, and time-consuming synthetic efforts.

A Unified Software Platform for Laboratory Informatics
Graham A. McGibbon, Hans de Bie, David Hardy, Ryan Sasaki, Patrick Wheeler, Carol Preisig

Reported here are capabilities in automated workflows involving analytical data with chemical structures. Specifically described is automated homogenization of data from a set of instruments, including NMR structure verification, as one solution.

Rapid electrochemical impedance spectroscopy for protein detection in Lab-on-a-Chip devices
T. Pardy(a); N. Sleptsuk(a); M. Min(a); J. Ojarand(a); T. Lakspere(a,b); K. Palm(b)

We present results in rapid solution impedance spectroscopy to detect protein interactions (antibody-antigen) in human serum. Two different serum-antibody mixtures are measured in cuvettes, interfaced with screen-printed electrodes to determine whether the experimental setup can detect differences in composition.

Advanced Microfluidic Mixing Device for the Study of Macromolecule Dynamics
Shubha Jain, F. Azam, Dr. H. N. Unni

We have developed and characterized a micro-fluidic mixer to study the macro-molecule dynamics such as kinetics of protein folding, DNA sequencing, single molecule study and detection etc. on a micro-second timescale. Numerical simulation has been performed to analyse the study of mixing performance of micro-fluidics channel.

<< 1 2 3 4 5 6 7 >>
Showing Results 11 - 20 of 320
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!